公开(公告)号：US07335776B2

公开(公告)日：2008-02-26

申请号：US10471553

申请日：2002-03-13

申请人： Shigeyuki Nonaka ,  Takayuki Maruyama

发明人： Shigeyuki Nonaka ,  Takayuki Maruyama

IPC分类号： C07D277/04 ,  C07D277/08 ,  A61K31/425 ,  A01N43/78

CPC分类号： C07D277/36 ,  A61K31/341 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4439

摘要： A pharmaceutical composition for the treatment and/or prevention of depression comprising a compound having an antagonistic activity for EP1 receptor which a prostaglandin E2 receptor subtype.EP1 antagonist is useful for the treatment of depression, for example, endogenous depression, reactive depression, weatherability depression, neurological depressed state, the depressed state of brain organic mental disorder.

摘要翻译： 用于治疗和/或预防抑郁症的药物组合物，其包含前列腺素E 2受体亚型的具有拮抗活性的化合物。 EP 1拮抗剂可用于治疗抑郁症，例如内源性抑郁症，反应性抑郁症，耐候性抑郁症，神经性抑郁状态，脑有机精神障碍的抑郁状态。

公开(公告)号：US20060100195A1

公开(公告)日：2006-05-11

申请号：US10495979

申请日：2002-11-18

申请人： Takayuki Maruyama ,  Shigeyuki Nonaka

发明人： Takayuki Maruyama ,  Shigeyuki Nonaka

IPC分类号： A61K31/554 ,  A61K31/195 ,  A61K31/497

CPC分类号： A61K31/19 ,  A61K31/501 ,  A61K31/553

摘要： The present invention relates to an agent for the treatment and/or prevention of pollakiuria comprising a compound having an antagonism to an EP1 receptor which is a prostaglandin E2 receptor subtype. A compound having an antagonism to an EP1 receptor antagonistically acts on an EP1 receptor which is a prostaglandin PGE2 receptor subtype and significantly shows a suppressive activity for urination frequency in models where pollakiuria is induced. Therefore, it is effective for the treatment and/or prevention of pollakiuria (that which is due to nurogenic bladder, nervous bladder, stimulated bladder, unstable bladder, benign prostatic hypertrophy, etc.).

摘要翻译： 本发明涉及用于治疗和/或预防尿频的药剂，其包含对作为前列腺素E 2受体亚型的EP 1受体具有拮抗作用的化合物。 具有拮抗EP 1受体的化合物拮抗作用于作为前列腺素PGE 2受体亚型的EP 1受体，并显着地显示出 引起尿频的模型中排尿频率的抑制活性。 因此，对于尿尿症（由于神经源性膀胱，神经性膀胱，刺激性膀胱，膀胱不稳定，良性前列腺肥大等引起）的治疗和/或预防是有效的。

公开(公告)号：US20070167500A1

公开(公告)日：2007-07-19

申请号：US10562126

申请日：2004-06-25

申请人： Takayuki Maruyama ,  Michiyoshi Kobayashi ,  Shigeyuki Nonaka ,  Hiroki Okada ,  Takashi Konemura

发明人： Takayuki Maruyama ,  Michiyoshi Kobayashi ,  Shigeyuki Nonaka ,  Hiroki Okada ,  Takashi Konemura

IPC分类号： A61K31/426 ,  A61K31/195 ,  A61K31/18

CPC分类号： A61K45/06 ,  A61K31/195 ,  A61K31/277 ,  A61K2300/00

摘要： A preventive and/or a remedy for urinary tract diseases with symptoms such as urgency of urination, bladder pain, frequent urination or urine incontinence which comprises a combination of compound having antagonism to EP1 with another compound having antagonism to EP3 each selected from among prostaglandin E2 receptors. The combination of an EP1 antagonist with an EP3 antagonist is useful in preventing and/or treating urinary tract diseases with symptoms such as urgency of urination, bladder pain, frequent urination or urine incontinence, because of showing effect of improving urine retaining ability, improving bladder compliance, relieving hypertonic detrusor muscle and normalizing bladder perception.

摘要翻译： 具有诸如排尿紧急，膀胱疼痛，尿频排尿或尿失禁等症状的尿路疾病的预防和/或补救措施，其包括与具有拮抗作用的另一化合物的化合物的组合 至每个选自前列腺素E 2受体的EP 3。 EP 1拮抗剂与EP 3拮抗剂的组合可用于预防和/或治疗尿路疾病，其症状如排尿紧急，膀胱疼痛，尿频 或尿失禁，因为具有改善尿液保留能力，改善膀胱顺应性，缓解高渗性逼尿肌和正常化膀胱感觉的作用。